Sam Clark is a reporter specializing in data protection and security. He currently works for MLex, where he covers a range of topics related to data privacy and online safety. His work has also been featured in publications such as Runner's World Magazine and Coastal View News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Sam's coverage heavily focuses on government announcements and legal policy regulations, with a keen interest in data privacy, EU regulations, GDPR, technology companies, and the telecom industry. Given this focus, he would likely be interested in expert commentary from individuals well-versed in these areas.
Considering Sam's extensive coverage of government announcements and legal policy regulation related to data privacy and technology companies within the EU context, experts with insights into the implications of new regulations or significant legal developments would likely resonate well with his coverage interests.
Given that Sam does not have a specific geographic focus but instead covers EU-related topics extensively in his articles' titles suggests that he is more inclined towards covering regulatory matters at an international level rather than focusing on individual countries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Sam Clark, Andrew Cutler
Key Takeaways The FDA approved xanomeline and tropism chloride capsules, marking a new era in schizophrenia treatment with a novel pharmacological approach.
By: Rishi Kakar, Sam Clark, Andrew Cutler
In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.
By: Andrew Cutler, Rishi Kakar, Sam Clark
In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.
By: Andrew Cutler, Rishi Kakar, Sam Clark
In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.
By: Rishi Kakar, Sam Clark, Andrew Cutler
In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.
New leadership in Dublin has put the EU's privacy regulators on a collision course with Big Tech.
By: Sam Clark
Stockholm is asking the EU and other capitals to force tech platforms to stop recruitment by crime gangs.
Chelsea Winter's latest book is designed to suit every style of eater.
By: Barbara Moens, Sam Clark
“I'm really scared by digital platforms in bad hands,” Věra Jourová tells POLITICO.
By: Sam Clark
Věra Jourová lands in the tech chief's crosshairs after criticizing him for actively “helping” villains.
(833) 317-6278 
